A U.S. appeals court has reinstated more than 500 lawsuits against drugmaker Merck & Co. because of its osteoporosis drug Fosamax, which plaintiffs allege increases risk of thigh bone fractures, ...
Shares of Merck & Co. Inc. MRK shed 1.31% to $115.63 Monday, on what proved to be an all-around great trading session for the ...
The decision, which the U.S. Court of Appeals for the Third Circuit said was a close call, hinged on whether an informal ...
Benzinga is an innovative financial news outlet that has become the first choice for brokerages given its easy-to-integrate API suite and easy-to-consume content. Benzinga provides timely, actionable ...
A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.
More than 500 lawsuits, which a U.S. appeals court revived on Friday, allege Merck & Co. failed to warn patients that its osteoporosis drug Fosamax raised the risk of thigh bone fractures. Separately, ...
A dark-money group has launched a multi-state bus tour to bring awareness to what they characterize as bad behavior by pharma ...
The Mumbai-based startup’s products use AI to help identify and manage critical diseases at more than 3,000 imaging sites in ...
EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback